Chapter 17 — Further Reading

Start here: do the search yourself

This is the chapter's most valuable recommendation, and it is not a reading list. It is an instruction.

Everything in this chapter's rating rests on a single verifiable claim: that as of this writing there is no completed, peer-reviewed, randomized controlled human trial of BPC-157 in the published literature. You should not take that from me. It is date-stamped precisely so that you can check it, and checking it takes about ten minutes.

On PubMed — pubmed.ncbi.nlm.nih.gov, free, no account needed:

1. Search BPC-157. Note the total number of results. It will look substantial, and it is.
2. In the left-hand filter panel, apply Article type → Randomized Controlled Trial. Watch the number change.
3. Now also apply Species → Humans. Watch it change again.
4. Open whatever survives both filters and read the Methods section for the sentence naming the subjects. Indexing is imperfect and filters are not infallible; the methods section is the authority. If it says rats, mice, or rabbits, it is animal-rung work regardless of how it was tagged.
5. Repeat the whole sequence with alternate identifiers — "BPC 157" without the hyphen, "pentadecapeptide BPC 157", "body protection compound", and any development code you encounter. Compounds hide under several names, and a single-name search misses them.

On ClinicalTrials.gov — free, no account needed:

1. Search BPC-157.
2. On every hit, read the Recruitment status field: Not yet recruiting / Recruiting / Enrolling by invitation / Active, not recruiting / Suspended / Terminated / Withdrawn / Completed / Unknown status. "Unknown status" means the sponsor stopped updating the record.
3. For anything marked Completed, look for a Study Results tab. Its presence or absence is the whole question.
4. Internalize the five distinct states: registered ≠ run ≠ completed ≠ results posted ≠ peer-reviewed publication. Only the last one settles anything, and a claim that "there's a trial registered" is compatible with there being no data at all.

Then widen the net. The WHO International Clinical Trials Registry Platform (ICTRP) aggregates national registries worldwide, and the EU Clinical Trials Register covers European studies. A trial run outside the United States would appear in one of these. Search all three before concluding anything.

Finally, write down the date and what you found. You now have a dated, checkable finding of your own rather than a claim you accepted. If your result differs from this chapter's, yours is the current one — and §17.11 tells you exactly what a positive, negative, or low-quality result would each mean.

Do the same exercise for semaglutide immediately afterward, as a calibration. The contrast between the two search results, performed back to back in the same session, teaches more about the evidence ladder than any number of pages about it.

Tier 1 — Verified canonical

The primary literature itself. The animal research on BPC-157 is indexed on PubMed and much of it is available in full text. This chapter has deliberately not summarized individual papers, because the skill being taught is reading them yourself. Pick two or three from different model families — one tendon, one gastrointestinal — and read them properly: the methods section first, then the results, then the authors' own limitations paragraph last. That limitations paragraph is the most honest text in the entire information chain and the first thing lost downstream (Chapter 6). Notice how careful the authors are, and compare that care to any consumer-facing summary of the same work.

On the translation problem in general. The failure of preclinical results to predict human outcomes is a large and well-developed literature in its own right, indexed on PubMed under terms such as translational failure, preclinical reproducibility, and animal-to-human translation. The ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) are the standard reporting framework for animal studies and are free online; reading the guidelines is an efficient way to learn what a well-reported animal study should contain, which in turn tells you what to look for when it is missing.

On tendinopathy. The shift from "tendinitis" to "tendinopathy" and the evidence base for progressive loading programs are covered in the sports and musculoskeletal medicine literature and in standard clinical practice guidelines. The VISA-A questionnaire, the validated patient-reported instrument referenced in §17.11, is documented in the peer-reviewed literature along with its measurement properties and its minimal clinically important difference — a worthwhile read for anyone who wants to understand what "a clinically meaningful endpoint" actually means in practice.

On what clinical trial phases are. The U.S. National Institutes of Health and the FDA both publish free plain-language material on trial phases, what a Phase I study is for, and what registration and results reporting obligations exist. Ten minutes here makes the phrase "there is no published Phase I" concrete rather than abstract.

On regulatory status. National regulators publish their current positions on unapproved substances and on which bulk substances may be used in compounded preparations; anti-doping authorities publish a prohibited list annually in which any pharmacological substance without current approval for human therapeutic use is prohibited at all times. Both change, and both are published in full. If your circumstances depend on either — you are subject to testing, or you are being offered a compounded preparation — read the current document rather than a summary of it. This book deliberately makes no claim about what those documents currently say.

Tier 2 — Attributed, specifics unverified

Reviews of the BPC-157 literature. Several narrative reviews of the preclinical work exist and are indexed. They are useful for orientation and they are the exact place where §17.6's citation drift begins, so read them with a specific discipline: every time you meet a claim of efficacy, find the species. If the review's own summary sentences omit it, note that, and note how natural the omission feels. That observation is worth more than the review's content.

Journalism about the compound. Coverage exists in both of Chapter 6's registers — the miracle version and the menace version. Reading one of each, consecutively, is a useful exercise: identify the overclaim in each, and notice that the cautionary piece typically commits its own, converting "no human safety data" into "dangerous." Neither register is written by people trying to mislead you, and both do.

Practitioner and clinic material. Some clinics publish patient-facing explanations of peptide therapies. Read these as primary sources about the information environment rather than as sources about the science. The specific thing to watch for is the sentence that describes preclinical findings in the present tense with no subject — the level-④ sentence from Case Study 1's ladder.

Tier 3 — Illustrative and constructed

Case Study 1's rodent tendon study is a composite: the design, model, outcomes, and reported pattern follow the real shape of this literature, and the specific numbers are constructed. It is labeled as such at the top of the file and again inside the figure. It exists so that a study can be examined in full without misrepresenting any particular group's work, and every conclusion drawn from it depends on the design rather than on the invented figures.

Figure 17.1 in the chapter, the gastroprotection study, is a composite on the same terms.

Case Study 2 is a structural analysis of an information environment rather than a report on particular vendors, forums, publications, or people, none of which are named. The claims discussed are paraphrased composites of types that circulate widely.

The paraphrased claims in exercise section F are likewise composites, written so that they belong to no identifiable person. They are constructed to be the strongest and most common versions of their type, not the weakest — which is why several of them contain something true.

A closing note on what to read next

If you finish this chapter wanting more certainty about BPC-157 specifically, the honest answer is that reading more will not supply it, because the information that would settle the question has not been generated. What reading can do is make you faster and more accurate on the next compound.

For that, Chapter 18 is the immediate sequel — TB-500 and thymosin β4, a structurally different molecule with a partially overlapping set of claims and a very similar evidence situation, presented with much less scaffolding so that you run the procedure yourself. Chapter 19 covers the gray market as its own subject. And Chapter 34 covers what is actually in a vial, which is a question entirely independent of everything in this chapter and, on the current evidence, the one that has caused the documented harm.